Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Common Equity (2020 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Common Equity for 6 consecutive years, with $56.1 billion as the latest value for Q3 2025.

  • Quarterly Common Equity rose 23.35% to $56.1 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $56.1 billion through Sep 2025, up 23.35% year-over-year, with the annual reading at $56.1 billion for FY2025, 23.35% up from the prior year.
  • Common Equity hit $56.1 billion in Q3 2025 for Universe Pharmaceuticals, up from $45.5 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $56.1 billion in Q3 2025 to a low of $47.0 million in Q3 2021.
  • Historically, Common Equity has averaged $33.0 billion across 5 years, with a median of $35.3 billion in 2022.
  • Biggest five-year swings in Common Equity: surged 75083.64% in 2022 and later dropped 20.83% in 2023.
  • Year by year, Common Equity stood at $47.0 million in 2021, then soared by 75083.64% to $35.3 billion in 2022, then dropped by 20.83% to $28.0 billion in 2023, then skyrocketed by 62.68% to $45.5 billion in 2024, then grew by 23.35% to $56.1 billion in 2025.
  • Business Quant data shows Common Equity for UPC at $56.1 billion in Q3 2025, $45.5 billion in Q3 2024, and $28.0 billion in Q3 2023.